[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
April 5, 2000

Advisory Committee Meeting

Author Affiliations
 

Not Available

Not Available

JAMA. 2000;283(13):1679. doi:10.1001/jama.283.13.1679-JFD00002-3-1

The FDA's Urology Subcommittee of the Advisory Committee for Reproductive Health Drugs will hold an open meeting on April 10, 9 AM to 5 PM, at the Holiday Inn, 8120 Wisconsin Ave, Bethesda, Md. The committee will consider the safety and efficacy of new drug application for apomorphine hydrochloride tablets, sublingual (Uprima, TAP Holdings Inc, Deerfield, Ill) proposed for use in the treatment of erectile dysfunction. Oral presentations from the public will be scheduled from 1 PM to 2 PM.

First Page Preview View Large
First page PDF preview
First page PDF preview
×